MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from maturitiesof investments$50,000K Proceeds from exercise ofcommon stock options$206K Proceeds from exercise ofcommon stock warrants$31K Net cash provided byinvesting activities$34,519K Net cash provided byfinancing activities$34K Canceled cashflow$15,481K Canceled cashflow$203K Net change in cashand cash...-$20,512K Canceled cashflow$34,553K Stock-based compensation$5,325K Accounts payable$4,080K Prepaid clinical trialcosts-$3,522K Amortization of debt issuancecosts and discount$1,252K Payment-in-kind interest$325K Depreciation$47K Purchases of investments$15,196K Purchases of property andequipment$249K Purchases of capitalizedsoftware$36K Payments for secondaryregistration statement costs$203K Net cash used inoperating activities-$55,065K Canceled cashflow$14,551K Net loss-$52,841K Accrued clinical trialcosts-$8,055K Other accruedexpenses-$6,858K Other current assets$976K Non-cash interest income$883K Non-cash operating leaseexpense-$3K
Cash Flow

Celcuity Inc. (CELC)

Celcuity Inc. (CELC)

source: myfinsight.com